| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| IO Biotech Inc. | IO102-IO103 with pembrolizumab - (basket trial) | Metastatic solid tumors | Phase 2 | Enrollment Conclusion | Intravenous | Oncology |
| Ionis Pharmaceuticals Inc. | AKCEA-TTR-LRx - (CARDIO-TTRansform) | ATTR cardiomyopathy | Phase 3 | Subcutaneous | Genetic Disorder | |
| Ionis Pharmaceuticals Inc. | IONIS-AGT-LRx | Hypertension | Phase 2b | Ongoing | Subcutaneous | Cardiology |
| Ionis Pharmaceuticals Inc. | IONIS-MAPTRx (ISIS 814907; BIIB080) - (CELIA) | Alzheimer's disease | Phase 2 | Data Released | Intrathecal | Neurology |
| Ionis Pharmaceuticals Inc. | ION449 (AZD8233) - (ETESIAN) | Dyslipidaemia | Phase 2b | Data Released | Subcutaneous | Cardiology |
| Ionis Pharmaceuticals Inc. | AKCEA-TTR-LRx - (CARDIO-TTRansform) | ATTR cardiomyopathy | Phase 3 | Subcutaneous | Genetic Disorder | |
| Ionis Pharmaceuticals Inc. | SPINRAZA (Nusinersen) - (DEVOTE) | Spinal muscular atrophy (SMA) | PDUFA | Intrathecal | Genetic Disorder | |
| Ionis Pharmaceuticals Inc. | eplontersen - (CARDIO-TTRansform) | Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults. | Phase 3 | Ongoing | Subcutaneous | Cardiology |